A Tumor Agnostic Therapeutic Strategy for Hexokinase 1–Null/Hexokinase 2–Positive Cancers
- 1 December 2019
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 79 (23) , 5907-5914
Abstract
Since Warburg's observation that most cancers exhibit elevated glycolysis, decades of research have attempted to reduce tumor glucose utilization as a therapeutic approach. Hexokinase (HK) activity is the first glycolytic enzymatic step; despite many attempts to inhibit HK activity, none has reached clinical application. Identification of HK isoforms, and recognition that most tissues express only HK1 while most tumors express HK1 and HK2, stimulated reducing HK2 activity as a therapeutic option. However, studies using HK2 shRNA and isogenic HK1+HK2− and HK1+HK2+ tumor cell pairs demonstrated that tumors expressing only HK1, while exhibiting reduced glucose consumption, progressed in vivo as well as tumors expressing both HK1 and HK2. However, HK1−HK2+ tumor subpopulations exist among many cancers. shRNA HK2 suppression in HK1−HK2+ liver cancer cells reduced xenograft tumor progression, in contrast to HK1+HK2+ cells. HK2 inhibition, and partial inhibition of both oxidative phosphorylation and fatty acid oxidation using HK2 shRNA and small-molecule drugs, prevented human liver HK1−HK2+ cancer xenograft progression. Using human multiple myeloma xenografts and mouse allogeneic models to identify potential clinical translational agents, triple therapies that include antisense HK2 oligonucleotides, metformin, and perhexiline prevent progression. These results suggest an agnostic approach for HK1−HK2+ cancers, regardless of tissue origin.Keywords
Funding Information
- DOD Peer Reviewed Cancer Research Program (W81XWH-16-1-0162)
This publication has 44 references indexed in Scilit:
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012
- Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAILOncogene, 2012
- Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer ModelsMolecular Cancer Therapeutics, 2011
- Metabolic Flux and the Regulation of Mammalian Cell GrowthCell Metabolism, 2011
- Subcellular Localization of Hexokinases I and II Directs the Metabolic Fate of GlucosePLOS ONE, 2011
- Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiformeJournal of Experimental Medicine, 2011
- Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysisNature Biotechnology, 2010
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- Hypoglycemia, functional brain failure, and brain deathJournal of Clinical Investigation, 2007
- Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondriaOncogene, 2006